bluebird bio Inc and Bristol-Myers Squibb Co to Provide Regulatory Update on Idecabtagene Vicleucel - Conference Call Transcript
Ladies and gentlemen, thank you for standing by, and welcome to the Bluebird Bio Regulator Update Call. (Operator Instructions)
I would now like to hand the conference over to your speaker, Ingrid Goldberg. Please go ahead.
Thank you. Good morning, everyone, and thank you for joining today's call. The format for today's call will be brief opening remarks from Nick. And then for the Q&A portion, we'll be joined by Dave and Chip as well as our Chief Business Officer and Head of Oncology, Joanne Smith-Farrell; and Chief Technology and Manufacturing Officer, Derek Adams.
Before we begin, I would like to remind everyone that we will make statements about the company's future plans and prospects that constitute forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those discussed in today's SEC filings. These forward-looking statements represent our estimates as of today and
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |